Table of Contents
Oral antifibrotics require high systemic dosing to achieve lung exposure, driving toxicity, discontinuation, and limiting the feasibility of combination therapy.
eSpraye is addressing that bottleneck with dry-powder inhaled fixed-dose combinations, co-forming multiple APIs into a single 1–5 μm particle delivered directly to the lung. The approach enables:
- Lower total doses
- Precise dose ratios
- One-puff BID combination therapy that isn’t tolerable orally
CEO Daniel Green discussed the science, regulatory strategy, and timing with Onyx at JPM 2026.
Comments